16 : From Prions to Parasites: Issues and Concerns in Blood Safety

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

From Prions to Parasites: Issues and Concerns in Blood Safety, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816957/9781555811419_Chap16-1.gif /docserver/preview/fulltext/10.1128/9781555816957/9781555811419_Chap16-2.gif


In recent years, blood safety has been the focus of increased attention. Blood safety issues have been numerous and varied and have encompassed a wide range of microorganisms and concerns. This chapter illustrates a variety of issues and challenges in this area, including those posed by emerging infections that may be transmissible by blood. Human immunodeficiency virus (HIV) strains are classified into different groups based on nucleic acid sequence analysis. HIV-I and HIV-2 are at the extreme of this diversity. Hepatitis G virus (HGY) and human herpesvirus 8 (HHY-8) are two newly discovered viruses that pose very different challenges to blood safety. HGY, a flavivirus, is fairly prevalent among blood donors; 1 to 2% of healthy blood donors have evidence of infection. Creutzfeldt-Jakob disease (CJD) is a rare, invariably fatal degenerative disease believed to be caused by an unconventional, disinfection-resistant infectious agent. Bacterial contamination can occur at one or more points in the collection, processing, pooling, and transfusion of blood. Several parasitic agents have recently caused concern for blood safety. The same approaches that have contributed to improved blood safety, including donor selection, testing, viral inactivation procedures, improved transfusion practices, and surveillance, are expected to continue to play a major role in dealing with these challenges and other potential threats to blood safety.

Citation: Khabbaz R, Chamberland M. 1998. From Prions to Parasites: Issues and Concerns in Blood Safety, p 295-310. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch16

Key Concept Ranking

Chagas' Disease
Human herpesvirus 8
Hepatitis C virus
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

Worldwide diversity of HIV isolates (reprinted from reference 40). HIV-1 group M subtypes A through I are represented on the map by letters A through I, and group O is represented by the letter O. The map is not an exhaustive list of all reported subtypes, nor does it include isolated reports or recently imported cases.

Citation: Khabbaz R, Chamberland M. 1998. From Prions to Parasites: Issues and Concerns in Blood Safety, p 295-310. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Alter, H. J.,, Y. Nakatsuji,, J. Melpolder,, J, Wages,, R. Wesley,, J. W. Shih,, and J. P. Kim. 1997. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N. Engl. J. Med. 336:747754.
2. Alter, H. J. 1997. G-pers creepers. where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion 37:569572. (Editorial).
3. Alter, H, J, 1995. To C or not to C: these are the questions. Blood 85:16811695.
4. Alter, M, J. 1995. Residual risk of transfusion-associated hepatitis, p. 23. In Programs and Abstracts of the NIH Consensus Development Conference on Infectious Disease Testing for Blood Transfusions. National institutes of Health, Bethesda, Md.
5. Alter, M. J.,, M. Gallagher,, T. T. Morris,, L. A. Moyer,, E. L. Meeks,, K. Krawczynski,, J. P. Kim,, and H. S. Margolis. 1997. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N. Engl. J. Med. 336:741746.
6. AuBuchon, J. P. 1997. Blood transfusion options: improving outcomes and reducing costs. Arch. Pathol. Lab. Med. 121:4047.
7. Barrett, B. B.,, J. W. Andersen,, and K. C. Anderson. 1993. Strategies for the avoidance of bacterial contamination of blood components. Transfusion 33:228233.
8. B1ackbourn, D. J.,, J. Ambroziak,, E. Lennette,, M. Adams,, B. Ramachandran,, and J. A. Levy. 1997. Infectious human herpesvirus 8 in a healthy North American blood donor. Lancet 349:609611.
9. Brashear, R. J.,, M. A. Winkler,, J. D. Schur,, H. Lee,, J. D. Burczak,, H. J. Hall,, and A. A. Pan. 1995. Detection of antibodies to Trypanosoma cruzi among blood donors in the southwestern and western United States. I. Evaluation of the sensitivity and specificity of an enzyme immunoassay for detecting antibodies to T. cruzi. Transfusion 35:213218.
10. Bresee, J. S.,, E. E. Mast,, P. J. Coleman,, M. J. Baron,, L. B. Schonberger,, M. J. Alter,, M. M Jonas,, M. Y. Yu,, P. M. Renzi,, and L. C. Schneider. 1996. Hepatitis C virus infection associated with administration of intravenous immune globulin: a cohort study. JAMA 276:15631567.
11. Busch, M. P.,, S. L. Stramer,, and S. H. Kleinman,. 1997. Evolving applications of nucleic acid amplification assays for prevention of virus transmission by blood components and derviatives, p. 123176. In G. Garratty (ed.), Application of Molecular Biology to Blood Transfusion Medicine. American Association of Blood Banks, Bethesda, Md.
12. Busch, M. P.,, L. L. L. Lee,, G. A. Satten,, D. R. Henrard,, H. Farzadegan,, K. E. Nelson,, S. Read,, R. Y. Dodd,, and L. R. Petersen. 1995. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type I seroconversion: implications for screening of blood and tissue donors. Transfusion 35:9197.
13. Busch, M. P.,, S. A. Glynn,, and G. B. Schreiber. 1997. Potential increased risk of virus transmission due to exclusion of older donors because of concern over Creutzfeldt-Jakob disease. Transfusion 37:9961002.
14.Centers for Disease Control. 1990. Human T-lymphotropic virus type I screening in volunteer blood donors—United States, 1989. Morb. Mortal. Weekly Rep. 39:915.
15.Centers for Disease Control. 1991. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. Morbid. Mortal. Weekly Rep. 40(RR-4):117.
16.Centers for Disease Control and Prevention. 1996. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices. Morbid. Mortal. Weekly Rep. 45(RR-15):130.
17.Centers for Disease Control and Prevention. 1996. Identification of HIV-1 group O infection—Los Angeles County, California. Morbid. Mortal. Weekly Rep. 45:561565.
18.Centers for Disease Control and Prevention. 1997. Red blood cell transfusions contaminated with Yersinia enterocolitica—United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. Morbid. Mortal. Weekly Rep. 46:553555.
19. Conry-Cantelina, C.,, J. C. Melpolder,, and H. J. Alter. 1997. Intranasal drug use among volunteer whole blood donors: results of a survey. Transfusion 37(9S):99S. (Abstract.)
20. Cossart, Y. E.,, A. M. Field,, B. Cant,, and D. Widdows. 1975. Parvovirus-like particles in human sera. Lancet i:7273.
21. Davanipour, Z.,, M. Alter,, E. Sobel,, D. M. Asher,, and D. C. Gajdusek. 1985. A case-control study of Creutzfeldt-Jakob disease. Dietary risk factors. Am. J. Epidemiol. 122:443451.
22. DeArmond, S. J.,, and S. P. Prusiner. 1995. Etiology and pathogenesis of prion diseases. Am. J. Pathol. 146:785811.
23. Dodd, R. Y., 1994. Adverse consequences of blood transfusion: quantitative risk estimates. p. 1. In S. T. Nance (ed.), Blood Supply Risks, Perceptions and Prospects for the Future. American Association of Blood Banks, Bethesda, Md.
24. Dodd, R. Y. 1995. Scaling the heights. Transfusion 35:186188. (Editorial).
25. Dodd, R. H.,, G. D. Griffin,, A. Conrad,, R. I. F. Smith,, P. L. Page,, and S. L. Stramer. 1997. Pilot study to determine the feasibility of PCR testing of pooled donor samples for HBV, HCV, HAV and parvovirus B19. Transfusion 37(9S):IS.(Abstract).
26. Dreslys, J. P.,, C. Lasmezas,, and D. Dormont. 1994. Selection of specific strains in iatrogenic Creutzfeldt-Jakob disease. Lancet 343:848849.
27. Eberhard, M. L.,, E. M. Walker,, and F. J. Steurer. 1995. Survival and infectivity of Babesia in blood maintained at 25°C and 2-4°C. J. Parasitol. 81:790792.
28. Esmonde, T. F.,, R. G. Will,, J. M. Slattery,, R. Knight,, R. Harries-Jones,, R. de Silva,, and W. B. Matthews. 1993. Creutzfeldt-Jakob disease and blood transfusion. Lancet 341:205207.
29. Evatt, B. Unpublished data.
30. Gao, S. J.,, L. Kingsley,, M. Li,, W. Zheng,, C. Parravicini,, J. Ziegler,, R. Newton,, C. R. Rinaldo,, A. Saah,, J. Phair,, R. Detels,, Y. Chang,, and P. S. Moore. 1996. KSHY antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat. Med. 2:925928.
31. Gerber, M. A.,, E. D. Shapiro,, P. J. Krause,, R. G. Cable,, S. J. Badon,, and R. W. Ryan. 1994. The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J. Infect. Dis. 170:231234.
32. Giacoia, G. P.,, and D. O. Kasprisin. 1989. Transfusion-acquired hepatitis A. South. Med. J. 82:13571360.
33. Gretch, D. 1997. Diagnostic tests for hepatitis C, p. 45. In Program and Abstracts of NIH Consensus Development Conference on Management of Hepatitis C. National Institutes of Health, Bethesda, Md.
34. Gunby, P. 1993. Desert Storm veterans now may donate blood; others call for discussion of donor tests. JAMA 269:451452.
35. Heye, N.,, S. Hensen,, and N. Muller. 1994. Creutzfeldt-Jakob disease and blood transfusion. Lancet 343:298299.
36. Herwaldt, B. L.,, A. M. Kjemtrup,, P. A. Conrad,, R. C. Barnes,, M. Wilson,, M. G. McCarthy,, M. H. Sayers,, and M. L. Eberhard. 1997. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WAI-type parasite. J. Infect. Dis. 175:12591262.
37. Herwaldt, B. L. Unpublished data.
38. Holman, R. C.,, A. S. Khan,, E. D. Belay,, and L. B. Schonberger. 1996. Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg. Infect. Dis. 2:333337.
39. Hoppe, P. A. 1992. Interim measures for detection of bacterially contaminated red cell components. Transfusion 32:199201. (Editorial).
40. Hu, D. J.,, T. O. Dondero,, M. A. Rayfield,, J. R. George,, G. Schocketman,, H. W. Jaffe,, E. C. Luo,, M. L. Kalish,, B. G. Weniger,, C. P. Pau,, C. A. Schable,, and J. W. Curran. 1996. The emerging genetic diversity of HIV: the importance of global surveillance for diagnostics, research, and prevention. JAMA 275:210216.
41.Institute of Medicine. 1995. HIY and the blood supply: an analysis of crisis decision making. National Academy Press, Washington, D.C.
42. Jagodzinski, L.,, F. Kraus,, and P. Garrett. 1994. Detection of hepatitis B viral sequences in early HBV infection. Transfusion 34(S):37S.
43. Kedda, M. A.,, M. C. Kew,, R. J. Cohn,, S. P. Field,, R. Schwyzer,, E. Song,, and F. Fernandes-Costa. 1995. An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as the source. Hepatology 22:13631367.
44. Kedes, D. H.,, E. Operskalski,, M. Busch,, R. Kohn,, J. Flood,, and D. Ganem. 1996. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nature Med 2:918924.
45. Kondo, K.,, and Y. Kuroiwa. 1982. A case control study of Creutzfeldt-Jakob disease: association with physical injuries. Ann. Neurol. 11:377381.
46. Lackritz, E. M.,, G. A. Satten,, J. Aberle-Grasse,, R. Y. Dodd,, V. P. Raimondi,, R. S. Janssen,, W. F. Lewis,, E. P. Notari IV,, and L. R. Petersen. 1995. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N. Engl. J. Med. 333:17211725.
47. Leiby, D. A.,, E. J. Read,, B. A. Lenes,, A. J. Yund,, R. J. Stumpf,, L. V. Kirchhoff,, and R. Y. Dodd. 1997. Seroepidemiology of Trypanosoma cruzi. etiologic agent of Chagas’ disease, in U.S. blood donors. J. Infect. Dis. 176:10471052.
48. Lennette, E.,, D. J. Blackbourn,, and J. A. Levy. 1996. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 348:858861.
49. Levy, R.,, A. Weissman,, G, Blomberg,, and Z. J. Hagay. 1997. Infection by parvovirus B19 during pregnancy: a review. Obstet. Gynecol. Surv. 52:254259.
50. Little, B. W.,, J. Mastrianni,, A. L. DeHaven, el al. 1993. The epidemiology of Creutzfeldt-Jakob disease in eastern Pennsylvania. Neurology 43:A316. (Abstract).
51. Luban, N. L. C. 1994. Human parvoviruses: implications for transfusion medicine. Transfusion 34:821827.
52. Magill, A. J.,, M. Grogl,, R. A. Gasser Jr,, W. Sun,, and C. N. Oster. 1993. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Stonn. N. Engl. J. Med. 328:13831387.
53. Magill, A. J.,, M. Grogl,, S. C. Johnson,, and R. A. Grasser. 1994. Visceral infection due to Leishmania tropica in veterans of Operation Desert Storm who presented 2 years after leaving Saudi Arabia. Clin. Infect. Dis. 19:805806.
54. Mannucci, P. M. 1993. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang. 64:197203.
55. Mannucci, P. M.,, S. Gdovin,, A. Gringeri,, M. Colombo,, A. Mele,, N. Schinaia,, N. Ciavarella,, S. U. Emerson,, and P. H. Purcell. 1994. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann. Intern . Med. 120:17.
56. Manuelides, E. E.,, J. H. Kim,, J. R. Mericangas,, and L. Manuelides. 1985. Transmission to animals of Creutzfeldt-Jakob disease from human blood. Lancet ii:896897.
57. Mintz, E. D.,, J. F. Anderson,, R. G. Cable,, and J. L. Hadler. 1991. Transfusion-transmitted babesiosis: a case report from a new endemic area. Transfusion 31:365368.
58. Morrow, J. F.,, H. G. Braine,, T. S. Kickler,, P. M. Ness,, J. D. Dick,, and A. K. Fuller. 1991. Septic reactions to platelet transfusions: a persistent problem. JAMA 266:555558.
59. O’Brien, T. R.,, J. R. George,, and S. D. Holmberg. 1992. Human immunodeficiency virus type 2 infection in the United States: epidemiology, diagnosis, and public health importance. JAMA 267:27752779.
60. Operskalski, E. A.,, M. P. Busch,, J. W. Mosley,, and D. Kedes. 1997. Blood donations and viruses. Lancet 349:1327.
61. Ragni, M. V.,, W. C. Koch,, and J. A. Jordan. 1996. Parvovirus B19 infection in patients with hemophilia. Transfusion 36:238241.
62. Pau, C. P.,, J. Hud,, C. Spruill,, C. Schabl,, E. Lackritz,, M. Kai,, J. R. George,, M. A. Rayfield,, T. J. Dondero,, A. E. Williams,, M. P. Busch,, A. E. Brown,, F. E. McCutchan, and G. Schochetman. 1996. Surveillance for human immunodeficiency virus type 1 group O infections in the United States. Transfusion 36:398400.
63. Popovsky, M. A. 1991. Transfusion-transmitted babesiosis. Transfusion 31:296298.
64. Schable, S.,, L. Zekeng,, P. Chou-Pong,, D. Hu,, L. Kaptue,, L. Gurtler,, T. Dondero,, J. M. Tsague,, G. Schochelman,, and H. Jaffe. 1994. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 344: 13331334.
65. Schmunis, G. A. 1991. Trypanosoma cruzi, the etiologic agent of Chagas’ disease: status in the blood supply in endemic and nonendemic countries. Transfusion 31:547557.
66. Schreiber, G. B.,, M. P. Busch,, S. H. Kleinman,, and J. J. Korelitz. 1996. The risk of transfusion-transmitted viral infections. N. Engl. J. Med. 334:16851690.
67. Schulman, I. A.,, M. D. Appleman,, S. Saxena,, A. L. Hiti,, and L. V. Kirchoff. 1997. Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion 37:727731.
68. Sloand, E. M.,, E. Pitt,, and H. G. Klein. 1995. Safety of the blood supply. JAMA 274:13681373.
69. Soucie, J. M.,, B. H. Robertson,, and B. P. Bell. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Submitted for publication.
70. Stramer, S. L.,, J. Haberle-Grasse,, J. P. Brodsky,, M. P. Busch,, and E. M. Lackritz. 1997. US blood donor screening with p24 antigen (Ag); one year experience. Transfusion 37(9S):IS. (Abstract.)
71. Stramer, S. L.,, R. A. Porter,, J. P. Brodsky,, A. Conrad,, G. F. Smith,, and R. Y. Dodd. 1997. Sensitivity of HIV and HCV detection by pooled PCR testing. Transfusion 37(9S):98S. (Abstract.)
72. Sullivan, M.,, A. Williams,, E. Guido,, R. Melter,, C. Schable,, and S. Stramer. 1997. Detection and characterization of an HIV type 2 antibody positive blood donor in the U.S. Transfusion 37(9S):58S. (Abstract.)
73. Sullivan, M. T.,, L. B. Schonberger,, D. Kessler,, A. E. Williams,, and R. Y. Dodd. 1997. Creutzfeldt-Jakob Disease (CJD) investigational look-back study. Transfusion 37(9S):2S. (Abstract.)
74. Sullivan, P. S.,, A. N. Do,, K. Robbins,, M. Kalish,, S. Subbarao,, D. Pieniazek,, C. Schable,, G. Afaq,, J. Markowitz,, R. Myers,, J. M. Joseph,, and G. Benjamin. 1997. Surveillance for variant strains of HIV: Subtype G and group O HIV-1. JAMA 278:292. (Letter.)
75. Tamai, Y.,, H. Kojuma,, R. Kitajima,, M. Kalish,, S. Subbarao,, D. Pieniazek,, C. Schable,, G. Afaq,, J. Markowitz,, R. Myers,, J. M. Joseph,, and G. Benjamin. 1992. Demonstration of the transmissible agent in tissue from a pregnant woman with Creutzfeldt-Jakob disease. N. Engl. J. Med. 327:649.
76. Tateishi, J. 1985. Transmission of Creutzfeldt-Jakob disease from human blood and urine into mice. Lancet ii:1074.
77. Tipple, M. A.,, L. A. Bland,, J. J. Murphy,, M. J. Arduino,, A. L. Panlilio,, J. J. Farmer III,, M. A. Tourault,, C. R. Macpherson,, J. E. Menitove,, and A. J. Grindon. 1990. Sepsis associated with transfusion of red cells contaminated with Yersinia enterocolitica. Transfusion 30:207.
78. Torok, T. J., 1995. Human parvovirus B19. p. 668702. In J. S. Remington, and J. O. Klein (ed.), Infectious Diseases of the Fetus and Newborn Infant. W. B. Saunders, Philadelphia, Pa.
79. Tuma, W.,, V. Schottstedt,, and G. Bunger. 1997. PCR mini-pool testing of all donations from a large blood bank. In Program of Cambridge Healthtech Institutes Conference on Blood Safety Screening. Cambridge Healthtech Institute, Newton Upper Falls. Mass.
80.U.S. General Accounting Office. 1997. Blood Supply: Transfusion-Associated Risks. Government Printing Office. Washington. D.C.
81. Wagner, S. J.,, L. I. Friedman,, and R. Y. Dodd. 1994. Transfusion-associated bacterial sepsis. Clin. Micro. Rev. 7:290302.
82. Williams, A. E.,, R. A. Thomson,, G. B. Schreiber,, M. J. Arduino,, A. L. Panlilio,, J. J. Farmer III,, M. A. TourauIt,, C. R. Macpherson,, J. E. Menitove,, and A. J. Grindon. 1997. Estimates of infectious disease risk factors in US blood donors. JAMA 277:967972.
83. Williams, M. D.,, B. J. Cohen,, A. C. Beddall,, K. J. Pasi,, P. P. Mortimer,, and F. G. Hill. 1990. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang. 58:177181.


Generic image for table
Table 1

Estimated risk and window period of infectivity for transmission of HIV, HBV, and HCV through transfusion

Citation: Khabbaz R, Chamberland M. 1998. From Prions to Parasites: Issues and Concerns in Blood Safety, p 295-310. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch16
Generic image for table
Table 2

CJD deaths and death rates by age group in the United States, 1979 to 1994

Citation: Khabbaz R, Chamberland M. 1998. From Prions to Parasites: Issues and Concerns in Blood Safety, p 295-310. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch16

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error